Kymera Therapeutics (KYMR) Misses Q3 EPS by 18c
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Join SI Premium – FREE
Kymera Therapeutics (NASDAQ: KYMR) reported Q3 EPS of ($0.94), $0.18 worse than the analyst estimate of ($0.76).
For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR) Following Sector Deal
- EU approves Arrowhead's plozasiran for rare triglyceride disorder
- OpenAI launches open-source security program with Trail of Bits
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
